Evidence map›Paper›PMID 42296399›Full record

ArticleJournal of medical Internet research2026

Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study.

Junhyuk Seo, Taerim Kim, Ju-Hyun Kim

Abstract readComparative Study
In one paragraph

Article in Journal of medical Internet research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Junhyuk Seo *Healthcare Research Institute, ETOILE Inc, Seoul, Republic of Korea.ORCID http://orcid.org/0009-0006-8289-4432
Taerim Kim *Healthcare Research Institute, ETOILE Inc, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-8340-9511
Ju-Hyun KimDepartment of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea, 82 10-9668-6227.ORCID http://orcid.org/0000-0003-4007-5739

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Administrative costs in the health care system are driven in part by complex insurance eligibility determinations. Large language models (LLMs) are increasingly used for health insurance-related queries, yet their reliability for structured logical reasoning over coverage criteria has not been systematically evaluated. Objective: This study aimed to develop a benchmark for anticancer drug reimbursement eligibility determination and evaluate whether LLMs can reliably perform eligibility verification. Methods: We constructed a benchmark based on South Korea's National Health Insurance reimbursement guidelines for 3 gynecologic cancers (cervical, uterine, and ovarian), using a tristate adjudication framework (eligible, ineligible, and undeterminable). Three gynecologic oncology experts and a utilization review nurse validated the benchmark. Six LLMs from 3 providers (Anthropic, Google, and OpenAI) were evaluated using the official guideline document as input. Each case was evaluated 3 times per model, with final predictions determined by majority vote, and performance was compared across the 3 outcome classes. Results: The benchmark comprises 74 anticancer regimens with 222 cases. Overall verification accuracy ranged from 77.9% to 88.7% across the 6 models. Eligible and ineligible cases were classified with high recall (86.5%-98.6%), but undeterminable cases showed a marked decline across all models (44.6%-70.3%). Performance varied by cancer type, with uterine cancer showing the lowest undeterminable recall (16.7%), corresponding to the highest guideline complexity. Undeterminable cases were predominantly misclassified as eligible rather than ineligible. The tristate framework enabled logic-based error analysis of 235 incorrect predictions, revealing information gap-filling as the dominant failure pattern (n=196, 83.4%), followed by criterion misapplication (n=20, 8.5%) and false uncertainty (n=19, 8.1%). Subtype analysis indicated that information gap-filling errors were concentrated at hierarchical elements of the guideline. Sensitivity analyses showed that converting the guideline document to structured text degraded performance, while web search-enabled condition (0%-3.2% tool invocation across models) and structure-guided prompting did not produce significant changes from baseline. Conclusions: In this benchmark, LLMs classified clearly eligible and ineligible cases with relatively high recall but showed limited reliability on undeterminable cases. The dominant error pattern was information gap-filling, in which models inferred eligibility rather than withholding judgment. These findings indicate that LLMs, in their current form, should be deployed as supervised decision-support tools rather than as independent adjudicators in reimbursement review.

Indexed as

Antineoplastic AgentsBenchmarkingEligibility DeterminationInsurance, Health, ReimbursementLarge Language ModelsFemaleHumansRepublic of KoreaAntineoplastic Agentsanticancer drugsbenchmarkclinical decision supporteligibility verificationgynecologic cancerhealth insurancelarge language modelsNational Health Insurancenatural language processingreimbursement

Identifiers

PMID42296399
PMCPMC13268259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.